This is a Provisional Conference Programme.
For further information on this event please contact us.
Day One
Tuesday 21st May 2024
09.00-10.00 Onwards
Registration
09.45-09.55
Welcome and Opening Remarks
Emanuele Montomoli
(VisMederi Srl, Siena, Italy)
09.55-10.00
‘VisMederi Foundation Presentation’
Veronica Cannucci
(VisMederi Srl, Siena, Italy)
Session 1: Opening Plenary
Moderator: Emanuele Montomoli
(VisMederi Srl, Siena, Italy)
10.00-10.30
KEYNOTE:
‘The role of inflammation in the T cell response to RNA vaccines for Influenza’
John Tregoning
(Imperial College, London, UK)
10.30-11.00
KEYNOTE:
‘A century of respiratory pandemics have driven major scientific discoveries in vaccines’
John Oxford
(Blizzard Institute, Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)
11.00-11.30
Coffee Break & Poster Setup
Session 2
Moderator: John Oxford
(Blizzard Institute, Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)
11.30-12.00
KEYNOTE:
‘Next-generation influenza vaccines: Developing influenza vaccines for the entire world’
Jessica Taaffe
(WHO, Geneva, Switzerland)
12.00-12.30
‘In vitro model systems for the assessment and exploration of viral vaccines’
Anke Huckriede
(University Medical Centre, Groningen, The Netherlands)
12.30-13.00
‘Clinical development update on OVX836: A T-cell based broad spectrum influenza vaccine‘
Nicola Groth and Alexandre Le Vert
(OSIVAX, Lyon, France)
13.00-14.00
Lunch Break & Posters
Session 3
Moderator: George Milne
(University of Western Australia, Perth, Australia)
14.00-14.30
‘Policy questions around mRNA-based influenza vaccines’
Pierre Gsell
(World Health Organisation, Geneva, Switzerland)
14.30-15.00
‘Protection against respiratory viruses by cross-reactive mucosal IgA’
Sean Tucker
(VAXART Inc, South San Francisco, California, USA)
15.00-15.30
’Characteristics of epitopes of limited variability on the head of influenza haemagglutinin’
Sunetra Gupta
(University of Oxford, Oxford, UK)
15.30-16.00
‘Influenza vaccination uptake in adults aged 35-65 years: A Norwegian population-based cohort study’
Anna Hayman Robertson
(Norwegian Institute of Public Health, Oslo, Norway)
16.00-16.15
Tea Break & Posters
Session 4
Moderator: Bram Palache
(IFPMA IVS Task Force, Geneva, Switzerland)
16.15-17.00
Special IFPMA Presentation:
‘How can we solve the discrepancy between progress in science, product development and the uptake in vaccines’
Bram Palache
(On behalf of IFPMA IVS Task Force, Geneva, Switzerland)
Day Two
Wednesday 22nd May 2024
SESSION 5
Moderator: Otfried Kistner
(Senior Consultant & Independent Vaccine Expert, Vienna, Austria)
09.15-09.45
‘Influenza vaccines assessment: Methods and criticals’
Alessandro Manenti
(VisMederi Srl, Siena, Italy)
09.45-10.05
‘Engineering a cleaved, prefusion-stabilized influenza B virus hemagglutinin by identification and locking of all six pH-switches’
Johannes Langedijk
(Janssen Vaccines, Leiden, The Netherlands)
10.05-10.25
‘Influenza B virus with a deletion in the NS1 C-terminal domain for the new live attenuated influenza vaccine’
Daria Shamakova
(Smorodintsev Research Institute of Influenza, St Petersburg, Russia)
10.25-10.50
Coffee Break & Posters
SESSION 6
Moderator: Irina Isakova-Sivak
(Institute of Experimental Medicine, Saint Petersburg, Russia)
10.50-11.20
‘Key findings from a comprehensive influenza vaccination modelling conducted for the Australian Department of Health’
George Milne
(University of Western Australia, Perth, Australia)
11.20-11.50
‘Prolonging the delivery of influenza virus vaccine improves the quantity and quality of the induced immune responses in mice’
Martin Beukema
(Univerity Medical Centre, Groningen, The Netherlands)
11.50-12.20
‘Development of cross-protective Type B live attenuated influenza vaccine candidates’
Pei-Fong Wong, Irina Isakova-Sivak, Ekaterina Stepanova, Ekaterina Bazhenova and Larisa Rudenko
(Institute of Experimental Medicine, Saint Petersburg, Russia)
12.20-13.30
Lunch Break & Posters
SESSION 7
Moderator: Anke Huckriede
(University Medical Centre, Groningen, The Netherlands)
13.30-14.00
‘Novavax investigational influenza vaccine and COVID and influenza combination vaccine development update’
Alessandro Perretti
(Novavax Inc., Gaithersburg, Maryland, USA)
14.00-14.30
‘Novel influenza vaccines: Impact on serological analysis and immune correlates’
Otfried Kistner
(Senior Consultant & Independent Vaccine Expert, Vienna, Austria)
14.30-15.00
‘Pandemic preparedness: From proof of concept to clinic’
Leon de Waal
(Cerba Research, Schajik, The Netherlands)
SESSION 8
Moderator: Sunetra Gupta
(University of Oxford, Oxford, UK)
15.00-15.30
‘Prevalence of influenza B/Yamagata viruses from season 2012/2013 to 2021/2022 in Italy as an indication of a potential lineage extinction’
Serena Marchi
(University of Siena, Siena, Italy)
15.30-16.00
‘Antigenic sin drives B cell evolution: Lessons learned from the COVID-19 pandemic’
Emanuele Andreano
(Fondazione Toscana Life Sciences, Siena, Italy)
16.00-16.30
‘Influenza, COVID-19, RSV – the right time for novel combination vaccines?’
Otfried Kistner
(Senior Consultant & Independent Vaccine Expert, Vienna, Austria)
16.30
IVW 2024 Aperitif Social Event sponsored by VisMederi Srl
Day Three
Thursday 23rd May 2024
SESSION 9
Moderator: John Tregoning
(Imperial College, London, UK)
09.15-09.45
‘Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen’
Roland Zhan
(Janssen vaccines and Prevention BV, Leiden, The Netherlands)
09.45-10.15
‘Broadly reactive mRNA vaccines encoding conserved influenza and SARS-CoV-2 internal proteins induce functional T cell responses in ferrets and HLA-A2 transgenic mice’
Caroline de Melo
(Dutch National Institute for Public Health and the Environment (RIVM), Biltohoven, Utrecht, The Netherlands)
10.15-10.45
‘Adjuvanted nanoliposomes co-displaying six hemagglutinins and neuraminidases as a seasonal influenza virus vaccine’
Zachary Sia
(POP Biotechnologies, Inc., University of Buffalo, Bufallo, New York, USA)
10.45-11.15
Coffee Break & Posters
SESSION 10
Moderator: Otfried Kistner
(Senior Consultant & Independent Vaccine Expert, Vienna, Austria)
11.15-11.45
‘Humoral immune response to Influenza Vaccination in repeatedly vaccinated adults during four consecutive epidemic seasons’
Mariia Sergeeva
(Smorodintsev Research Institute of Influenza, St Petersburg, Russia)
11.45-12.15
‘Vector Institute, from its conception in 1988 to the commercialization of the EpiVacCorona Vaccine in 2021’
Micha Roumantzeff
(MichaAdvices, Lyon, France)
12.15-13.15
Lunch Break & Poster Breakdown
SESSION 11
Moderator: To be confirmed
13.15-13.45
‘Modelling SARS-CoV-2 transmission reduction from social distancing and vaccination: 2020-2022’
George Milne
(University of Western Australia, Perth, Western Australia, Australia)
13.45-14.15
‘Development of a combined vaccine for simultaneous protection against seasonal influenza and COVID-19’
Irina Isakova-Sivak. Ekaterina Stepanova, Victoria Matyushenko, Daria Mezhenskaya, Ekaterina Bazhenova, Tatiana Kotomina, Alexandra Rak, Polina Prokopenko, Svetlana Donina, Anna Chistyakova, Arina Kostromitina, Vlada Novitskaya and Larisa Rudenko
(Institute of Experimental Medicine, St. Petersburg, Russia)
14.15-14.45
‘Towards the development of universal live attenuated influenzavaccine’
Vlada Novitskaya, Polina Prokopenko, Ekaterina Stepanova, Victoria Matyushenko, Alexandra Rak, Anna Chistyakova, Arina Kostromitina, Igor Kudryavtsev, Larisa Rudenko and Irina Isakova-Sivak
(Institute of Experimental Medicine, St. Petersburg, Russia)
14.45-15.00
Tea Break
SESSION 12: Closing Session
Moderator: Emanuele Montomoli
(VisMederi Srl, Siena, Italy)
15.00-15.30
‘Infectious pathogens and how we fight them’
John Tregoning
(Imperial College, London, UK)
15.30-16.00
CLOSING KEYNOTE:
‘An appraisal of anti-vaccination campaigns in the UK from Rider Haggard’s Dr Therne to the present and how they should not impede serious preparations for the next pandemic’
John Oxford
(Blizzard Institute, Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)
Closing Remarks & Departure
Posters
Poster 101
‘TRAP-cage – a novel artificial vaccination platform’
Izabela Stupka, Szymon Gaweł and Jonathan Heddle
(nCage Therapeutics, Krakow, Poland)
Poster 102
‘sHBsAg for influenza A mRNAs cargo’
Boguslaw Szewczyk
(University of Gdansk, Gdansk, Poland)
Poster 103
‘Improvement of licensed live attenuated influenza vaccine by targeted modification of viral NP and NS genes’
Polina Prokopenko
(The Federal State Budgetary Scientific Institution ‘Institute of Experimental Medicine’ (FSBSI ‘IEM’), St Petersburg, Russia)
Latebreaker abstracts for oral and poster presentation at IVW 2024 are called for. Please see the Participation page for details.
This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.